Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Multicenter Study to Investigate the Safety, Efficacy and Proof of Concept (POC) of Nivolumab Monotherapy as a Sequential Therapy Following Preoperative Chemoradiotherapy Patients With Locally Advanced Resectable Rectal Cancer

NCT02948348 is registered in ClinicalTrials.gov with Takayuki Yoshino as lead sponsor.

NCT NCT02948348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02948348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Multicenter Study to Investigate the Safety, Efficacy and Proof of Concept (POC) of Nivolumab Monotherapy as a Sequential Therapy Following Preoperative Chemoradiotherapy Patients With Locally Advanced Resectable Rectal Cancer
Lead sponsor
Takayuki Yoshino
Phase
Phase 1/2
Overall status
Unknown status
Start date
October 31, 2016
Completion date
August 31, 2022
Enrollment
90 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of rectum